Oral presentation of preclinical and preliminary toxicology data on its BET BD1 program at Discovery on Target 2016
Stockholm, 22 September 2016. Nuevolution AB (publ) (NUE.ST) will today present preclinical and preliminary toxicology data from its BET BD1 program at Discovery on Target 2016 (DoT 2016) in Boston, MA, USA. Jimmi G. Seitzberg, Project Manager, Nuevolution, will give an oral presentation reporting the key findings from the poster “NUE7770 - A BET-BD1 selective chemical probe with potent cellular and in vivo anti-inflammatory activity”, also including preliminary data from the first comparative animal toxicology study with NUE7770, selective BET BD1 inhibitor. The preliminary data from